Report Details:
15 Companies Covered
90 Pages
Market Research Future (MRFR) has published a cooked research report on the “Antipsychotic Drugs Market” that contains information from 2025 to 2035.
The Antipsychotic Drugs market is estimated to register a CAGR of 7.64% during the forecast period of 2025 to 2035.
MRFR recognizes the following companies as the key players in the Global Antipsychotic Drugs Market — H. Lundbeck A/S, Novartis, Acadia Pharmaceuticals, Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Mylan, Boehringer Ingelheim, Pfizer, Janssen Pharmaceuticals, AstraZeneca, Eli Lilly and Company, Roche, Otsuka Pharmaceutical, Lundbeck, and AbbVie.
Antipsychotic Drugs Market Highlights
The Antipsychotic Drugs Market is accounted for to register a CAGR of 7.64% during the forecast period and is estimated to reach USD 39.32 billion by 2035.
The market growth is driven by rising mental health awareness, increasing prevalence of conditions such as schizophrenia and bipolar disorder, and advancements in drug formulations, including long-acting injectables. Governments and healthcare organizations are prioritizing mental health and implementing policies that support treatment accessibility and affordability, leading to improved adoption of antipsychotic therapies. Increasing investment in research and development is expected to bring innovative, personalized drugs with improved safety and efficacy to the market.
Long-acting injectable antipsychotics continue to gain traction due to better treatment adherence and outcomes for chronic mental health patients. Telehealth services have broadened access to psychiatric care, encouraging individuals to seek medical support from remote locations. The growing shift toward generics and the development of novel delivery methods further support market expansion throughout the forecast period.
Segment Analysis
The Antipsychotic Drugs Market has been segmented based on Drug Type, Indication, Administration Route, Patient Age Group, and Region.
Based on Drug Type, the market has been segmented into Typical Antipsychotics, Atypical Antipsychotics, Long-acting Injectables, and Mood Stabilizers. Among these, the Atypical Antipsychotics segment is projected to dominate the Global Antipsychotic Drugs Market revenue through the projected period due to their enhanced tolerability and reduced side effects.
Based on Indication, the market has been segmented into Schizophrenia, Bipolar Disorder, Major Depressive Disorder, and Autism Spectrum Disorders. Among these, the Schizophrenia segment is projected to dominate the market during the forecast period due to its high prevalence and increasing diagnosis rates.
Based on Route, the market has been segmented into Oral, Injectable, Transdermal. Among these, the Oral segment is projected to dominate the market during the forecast period due to its high prevalence and increasing diagnosis rates.
Based on Patient Age Group, the market has been segmented into Pediatric, Adult, Geriatric. Among these, the Adult segment is projected to dominate the market during the forecast period due to its high prevalence and increasing diagnosis rates.
Region Analysis
By Region, the Antipsychotic Drugs market is segmented into North America, Europe, Asia Pacific, South America and the Middle East & Africa. The North America Antipsychotic Drugs market holds a considerable market share and is also forecasted to hold the largest share during the forecast period. Increased awareness of mental health, strong healthcare infrastructure, and supportive reimbursement systems are key contributing factors. Europe follows closely with significant demand for advanced psychiatric treatments. Asia Pacific is expected to grow steadily due to rising healthcare expenditure and expanding access to mental health services.
Key Findings of the Study
- The Global Antipsychotic Drugs Market is expected to reach USD 39.32 billion by 2035 at a CAGR of 7.64% during the forecast period.
- North America accounted for the leading market share in 2024.
- Based on Drug Type, the Atypical Antipsychotics segment was attributed to holding the largest market in 2024.
- Based on Indication, the Schizophrenia segment is projected to dominate the market through the forecast period.
- H. Lundbeck A/S, Novartis, Acadia Pharmaceuticals, Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Mylan, Boehringer Ingelheim, Pfizer, Janssen Pharmaceuticals, AstraZeneca, Eli Lilly and Company, Roche, Otsuka Pharmaceutical, Lundbeck and AbbVie are identified as key market players.